1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,900 | 26,000 | 02.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 18.02. | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated | 4 | GlobeNewswire (USA) | ||
| 17.02. | Oculis Holding AG: Oculis Appoints Katie Kazem as Chief Legal Officer | 321 | GlobeNewswire (Europe) | ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal... ► Artikel lesen | |
| OCULIS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Oculis gains on FDA breakthrough therapy status for optic neuritis therapy | 7 | Seeking Alpha | ||
| 06.01. | Why Oculis Is Rising In Pre-market? | 3 | RTTNews | ||
| 06.01. | Oculis Holding AG: Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis | 654 | GlobeNewswire (Europe) | ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing... ► Artikel lesen | |
| 09.12.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 12 | GlobeNewswire (USA) | ||
| 03.12.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 3 | GlobeNewswire (USA) | ||
| 28.11.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 18.11.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 3 | GlobeNewswire (USA) | ||
| 11.11.25 | Oculis Holding AG Q3 Loss Declines | 8 | RTTNews | ||
| 10.11.25 | Oculis Holding GAAP EPS of CHF -0.32 | 6 | Seeking Alpha | ||
| 10.11.25 | Oculis Holding AG: Oculis Reports Q3 2025 Financial Results and Provides Company Update | 461 | GlobeNewswire (Europe) | ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic... ► Artikel lesen | |
| 10.11.25 | Oculis Holding AG - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.10.25 | Oculis Holding AG: Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development | 415 | GlobeNewswire (Europe) | ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to... ► Artikel lesen | |
| 29.10.25 | Oculis Holding AG - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 14.10.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 8 | GlobeNewswire (USA) | ||
| 14.10.25 | Oculis Holding AG: Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 | 7 | GlobeNewswire (USA) | ||
| 08.10.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 07.10.25 | Oculis stock price target raised to $36 from $33 at H.C. Wainwright | 2 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,30 | +0,27 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| EVOTEC | 5,686 | -3,30 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| QIAGEN | 41,295 | -1,58 % | Shortseller-Positionen aktuell: freenet, GFT, HelloFresh, Hypoport, Puma, Qiagen, Redcare Pharmacy | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIOGEN | 161,20 | +0,19 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology |
SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 51,50 | -0,96 % | Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? | ||
| KUROS BIOSCIENCES | 29,940 | -0,13 % | Kuros Biosciences AG: Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences | Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences
Schlieren (Zürich), Switzerland, January 13, 2026 - Kuros Biosciences ("Kuros" or the "Company") a leader in innovative... ► Artikel lesen | |
| IDORSIA | 4,410 | -0,11 % | Idorsia verdoppelt 2025 Umsatz und reduziert den Verlust | Allschwil - Das Biotechunternehmen Idorsia schaut auf ein bewegtes 2025 zurück. Dabei ist es dem Unternehmen gelungen, weiter zu wachsen. Der Umsatz kletterte 2025 auf 221 Millionen Franken von 113... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 6,034 | +1,82 % | Telix Pharmaceuticals Limited: Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging | ||
| AC IMMUNE | 2,470 | 0,00 % | AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor | ||
| ZAI LAB LTD ADR | 15,900 | +0,63 % | Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028 | ||
| ARCTURUS THERAPEUTICS | 8,350 | 0,00 % | Arcturus Therapeutics Q4 2025 Earnings Preview | ||
| 3SBIO | 2,220 | +0,91 % | 3SBio Sells Shares, Divests Subsidiary To Boost Capital | ||
| AUTOLUS THERAPEUTICS | 1,450 | +1,40 % | Cellares Corp: Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform | Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage... ► Artikel lesen | |
| VTV THERAPEUTICS | 31,400 | -3,09 % | vTv Therapeutics Inc. - 8-K, Current Report | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 17,680 | 0,00 % | Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update |
OCULIS HOLDING AG gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 23,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OCULIS HOLDING AG finden Sie auf Wallstreet Online.